Home
NTLA
NTLA News

Latest Intellia Therapeutics Inc. (NTLA) News on February 5, 2025

MT Newswires

9 days ago

Intellia Therapeutics Shares Fall After Morgan Stanley Downgrade

MT Newswires

9 days ago

Update: Morgan Stanley Downgrades Intellia Therapeutics to Equal Weight From Overweight, Cuts Price Target to $11 From $56

MT Newswires

9 days ago

Morgan Stanley Downgrades Intellia Therapeutics to Equal Weight From Overweight, $56 Price Target

Intellia doses first subject in trial of NTLA-2002 for hereditary angioedema

Clinical Trials Arena

13 days ago

Intellia doses first subject in trial of NTLA-2002 for hereditary angioedema

NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate

Zacks

13 days ago

NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate

MT Newswires

14 days ago

Intellia Doses First Patient in Phase 3 Trial of Potential Treatment for Hereditary Angioedema

Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema

GlobeNewswire

14 days ago

Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema

Intellia makes progress on HAE study; 2 more China drug deals

BioPharma Dive

14 days ago

Intellia makes progress on HAE study; 2 more China drug deals

Intellia Loses 21.6% in a Week: How Should You Play the Stock?

Zacks

19 days ago

Intellia Loses 21.6% in a Week: How Should You Play the Stock?

The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK

Zacks

19 days ago

The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK

Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates

Zacks

20 days ago

Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates

Intellia slashes workforce by 27% to focus on late stage CRISPR candidates

Pharmaceutical Technology

23 days ago

Intellia slashes workforce by 27% to focus on late stage CRISPR candidates

Intellia Therapeutics price target lowered to $50 from $70 at BMO Capital

TipRanks

25 days ago

Intellia Therapeutics price target lowered to $50 from $70 at BMO Capital

Intellia Therapeutics price target lowered to $60 from $70 at Wells Fargo

TipRanks

25 days ago

Intellia Therapeutics price target lowered to $60 from $70 at Wells Fargo

Why Is Intellia Therapeutics Stock Trading Lower On Friday?

Benzinga

a month ago

Why Is Intellia Therapeutics Stock Trading Lower On Friday?

NTLA Announces Strategic Reorganization & Job Cuts in 2025, Stock Down

Zacks

a month ago

NTLA Announces Strategic Reorganization & Job Cuts in 2025, Stock Down

Intellia to stop work on rare disease therapy, lay off staff

BioPharma Dive

a month ago

Intellia to stop work on rare disease therapy, lay off staff

MT Newswires

a month ago

Intellia Therapeutics to Workforce by 27%, Halt Some Programs

Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)

GlobeNewswire

a month ago

Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)

MT Newswires

a month ago

BofA Securities Adjusts Price Target on Intellia Therapeutics to $50 From $58, Maintains Buy Rating

MT Newswires

a month ago

RBC Cuts Price Target on Intellia Therapeutics to $47 From $54, Keeps Outperform, Speculative Risk

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a month ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Why Is Intellia Therapeutics, Inc. (NTLA) Among the Top CRISPR Stocks to Invest In?

Insider Monkey

a month ago

Why Is Intellia Therapeutics, Inc. (NTLA) Among the Top CRISPR Stocks to Invest In?

Intellia Therapeutics, Inc. (NTLA): Is This Gene Therapy Stock a Good Buy Right Now?

Insider Monkey

a month ago

Intellia Therapeutics, Inc. (NTLA): Is This Gene Therapy Stock a Good Buy Right Now?

Here's Why We're Watching Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Situation

Simply Wall St.

a month ago

Here's Why We're Watching Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Situation

Intellia Crashes 60% in a Year: How Should You Play the Stock?

Zacks

2 months ago

Intellia Crashes 60% in a Year: How Should You Play the Stock?

Why Intellia Therapeutics (NTLA) Is the Worst ARK Stock to Buy According to Short Sellers

Insider Monkey

2 months ago

Why Intellia Therapeutics (NTLA) Is the Worst ARK Stock to Buy According to Short Sellers

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NTLA Up as FDA Grants RMAT Status to Genome-Editing Therapy

Zacks

2 months ago

NTLA Up as FDA Grants RMAT Status to Genome-Editing Therapy

BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug

Investor's Business Daily

2 months ago

BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug

MT Newswires

2 months ago

Sector Update: Health Care Stocks Rise in Monday Afternoon Trading

MT Newswires

2 months ago

Intellia Therapeutics' Nex-z Receives FDA Regenerative Medicine Advanced Therapy Designation

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

GlobeNewswire

2 months ago

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?

Motley Fool

2 months ago

Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?

Intellia Therapeutics Announces Promising CRISPR Therapy Results

TipRanks

3 months ago

Intellia Therapeutics Announces Promising CRISPR Therapy Results

ReCode to secure funds for cystic fibrosis gene correction treatments

Pharmaceutical Technology

3 months ago

ReCode to secure funds for cystic fibrosis gene correction treatments

Intellia Therapeutics price target lowered to $70 from $80 at Wells Fargo

TipRanks

3 months ago

Intellia Therapeutics price target lowered to $70 from $80 at Wells Fargo

Intellia’s gene editing therapy shows early potential in rare heart condition

Clinical Trials Arena

3 months ago

Intellia’s gene editing therapy shows early potential in rare heart condition

CRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest

BioPharma Dive

3 months ago

CRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

GlobeNewswire

3 months ago

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

Morningstar Research

3 months ago

Analyst Report: Intellia Therapeutics, Inc.

Morningstar Research

3 months ago

Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover

MT Newswires

3 months ago

Truist Securities Cuts Price Target on Intellia Therapeutics to $90 From $120, Maintains Buy Rating

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates

Simply Wall St.

3 months ago

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates

Intellia Therapeutics Inc (NTLA) Q3 2024 Earnings Call Highlights: Financial Stability and ...

GuruFocus.com

3 months ago

Intellia Therapeutics Inc (NTLA) Q3 2024 Earnings Call Highlights: Financial Stability and ...

NTLA's Q3 Earnings & Revenues Beat Estimates, Pipeline in Focus

Zacks

3 months ago

NTLA's Q3 Earnings & Revenues Beat Estimates, Pipeline in Focus

Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Tops Revenue Estimates

Zacks

3 months ago

Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Tops Revenue Estimates

Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

GlobeNewswire

3 months ago

Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day?

Motley Fool

3 months ago

Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day?

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

3 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Immatics (IMTX) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

3 months ago

Immatics (IMTX) Expected to Beat Earnings Estimates: Should You Buy?

This Beaten-Down Stock Could Soar by 354%, According to Wall Street

Motley Fool

3 months ago

This Beaten-Down Stock Could Soar by 354%, According to Wall Street

Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024

GlobeNewswire

3 months ago

Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024

Intellia Therapeutics (NTLA): Promising Gene Editing Stock with CRISPR-Cas9 Therapies

Insider Monkey

3 months ago

Intellia Therapeutics (NTLA): Promising Gene Editing Stock with CRISPR-Cas9 Therapies

Intellia Therapeutics Advances with Promising Phase 2 Results

TipRanks

3 months ago

Intellia Therapeutics Advances with Promising Phase 2 Results

Intellia reports positive data from Phase II study of NTLA-2002 for HAE

Clinical Trials Arena

3 months ago

Intellia reports positive data from Phase II study of NTLA-2002 for HAE

Morningstar Research

3 months ago

Analyst Report: Intellia Therapeutics, Inc.

Why Intellia Therapeutics Stock Plummeted by 20% Today

Motley Fool

3 months ago

Why Intellia Therapeutics Stock Plummeted by 20% Today

Intellia's Ntla-2002 Shows Promising Results, but Stock Drops Following Phase 2 Data Release

GuruFocus.com

3 months ago

Intellia's Ntla-2002 Shows Promising Results, but Stock Drops Following Phase 2 Data Release

Investing.com

3 months ago

Intellia Therapeutics stock plunges after phase 2 results from NTLA-2002 study

Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

GlobeNewswire

3 months ago

Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

Intellia data spark debate about CRISPR drug’s potential

BioPharma Dive

3 months ago

Intellia data spark debate about CRISPR drug’s potential

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

4 months ago

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

This Beaten-Down Growth Stock Could Skyrocket 234%, According to Wall Street

Motley Fool

4 months ago

This Beaten-Down Growth Stock Could Skyrocket 234%, According to Wall Street

Is Intellia Therapeutics, Inc. (NTLA) the Most Promising Biotech Stock According to Hedge Funds?

Insider Monkey

4 months ago

Is Intellia Therapeutics, Inc. (NTLA) the Most Promising Biotech Stock According to Hedge Funds?

Intellia Therapeutics Announces New Date for Upcoming Investor Webcast

GlobeNewswire

4 months ago

Intellia Therapeutics Announces New Date for Upcoming Investor Webcast

Intellia Therapeutics Inc (NTLA) Q2 2024 Earnings Call Highlights: Strategic Advances and ...

GuruFocus.com

4 months ago

Intellia Therapeutics Inc (NTLA) Q2 2024 Earnings Call Highlights: Strategic Advances and ...

2 Cathie Wood Stocks That Could Soar 32% and 282%, According to Wall Street

Motley Fool

4 months ago

2 Cathie Wood Stocks That Could Soar 32% and 282%, According to Wall Street

NTLA Begins Phase III Study on Hereditary Angioedema Candidate

Zacks

4 months ago

NTLA Begins Phase III Study on Hereditary Angioedema Candidate

Intellia Therapeutics begins Phase III trial of hereditary angioedema gene therapy

Clinical Trials Arena

4 months ago

Intellia Therapeutics begins Phase III trial of hereditary angioedema gene therapy

MT Newswires

4 months ago

Intellia Therapeutics Launches Phase 3 Trial of Investigational Hereditary Angioedema Treatment

Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

GlobeNewswire

4 months ago

Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

Intellia starts late-stage test of CRISPR therapy for rare swelling disease

BioPharma Dive

4 months ago

Intellia starts late-stage test of CRISPR therapy for rare swelling disease

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

4 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics (NASDAQ:NTLA shareholders incur further losses as stock declines 10% this week, taking three-year losses to 86%

Simply Wall St.

4 months ago

Intellia Therapeutics (NASDAQ:NTLA shareholders incur further losses as stock declines 10% this week, taking three-year losses to 86%

Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions

GlobeNewswire

4 months ago

Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions

2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk

Motley Fool

4 months ago

2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk

MT Newswires

5 months ago

JonesTrading Initiates Coverage on Intellia Therapeutics With Buy Rating, $41 Price Target

Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting

GlobeNewswire

5 months ago

Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting

The Brawl Taking Shape Over Pfizer’s Multibillion-Dollar Heart Monopoly

The Wall Street Journal

5 months ago

The Brawl Taking Shape Over Pfizer’s Multibillion-Dollar Heart Monopoly

Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) latest 6.7% decline adds to one-year losses, institutional investors may consider drastic measures

Simply Wall St.

5 months ago

Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) latest 6.7% decline adds to one-year losses, institutional investors may consider drastic measures

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

5 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics, Inc. (NTLA): Pioneering Gene Editing Solutions for Health Advancements

Insider Monkey

6 months ago

Intellia Therapeutics, Inc. (NTLA): Pioneering Gene Editing Solutions for Health Advancements

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Simply Wall St.

6 months ago

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Intellia's (NTLA) Q2 Earnings & Revenues Fall Shy of Estimates

Zacks

6 months ago

Intellia's (NTLA) Q2 Earnings & Revenues Fall Shy of Estimates

MT Newswires

6 months ago

RBC Cuts Price Target on Intellia Therapeutics to $54 From $60, Keeps Outperform, Speculative Risk

Morningstar Research

6 months ago

Analyst Report: Intellia Therapeutics, Inc.

Merck TIGIT drug fails another trial; Intellia therapy succeeds in HAE study

BioPharma Dive

6 months ago

Merck TIGIT drug fails another trial; Intellia therapy succeeds in HAE study

MT Newswires

6 months ago

Intellia Therapeutics Q2 Net Loss Widens, Revenue Falls

Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates

Zacks

6 months ago

Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates

Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress

GlobeNewswire

6 months ago

Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Motley Fool

6 months ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates

GlobeNewswire

6 months ago

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates

Vertex’s pain drug gets speedy FDA review; Keytruda hits a sales milestone

BioPharma Dive

6 months ago

Vertex’s pain drug gets speedy FDA review; Keytruda hits a sales milestone

MT Newswires

6 months ago

Intellia Therapeutics Receives Backing of UK Health Regulator to Conduct Trial of Gene Therapy

Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency

GlobeNewswire

6 months ago

Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency

Intellia (NTLA) to Report Q2 Earnings: What's in the Cards?

Zacks

6 months ago

Intellia (NTLA) to Report Q2 Earnings: What's in the Cards?

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

We're Keeping An Eye On Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Rate

Simply Wall St.

7 months ago

We're Keeping An Eye On Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Rate

Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product

Zacks

7 months ago

Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product

Share on Social Networks: